Sugi Predict

Sugi Predict / Compounds / SCHEMBL1315955

SCHEMBL1315955

SCHEMBL1315955

CC1CC(C(=O)O)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.43
▸ CHRM2 P08172 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NR1H2 P55055 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HTRA1 Q92743 1/20 0.37
▸ BTK Q06187 1/20 0.36
▸ HSD11B1 P28845 1/20 0.35
▸ UCHL1 P09936 1/20 0.34
▸ USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1294186 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL883116 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL1315957 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL3442335 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL15369826 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL24645252 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL8214873 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL933728 1.00 HSD17B10 (0.43) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL15673396 0.87 NR1H2 (0.41) HSD17B10CHRM2CHRM1CHRM3ATM
SCHEMBL193111 0.87 ATM (0.59) HSD17B10CHRM2CHRM1CHRM3ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 ZHOU YUHANG (US) 2025-09-11 — — US disclosed
US-20250059171-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 — — US disclosed
EP-4444711-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-10-16 — — EP disclosed
EP-4430035-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 Pharma LLC (US) 2024-09-18 — — EP disclosed
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 — — EP disclosed
WO-2023104882-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-15 — — WO disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
WO-2023086383-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2023-05-19 — — WO disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 — — CN disclosed
US-20130115193-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-09 — — US disclosed
CN-102712623-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2012-10-03 — — CN disclosed
EP-2499115-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 — — EP disclosed
EP-2499127-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 — — EP disclosed
WO-2012068234-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-05-24 — — WO disclosed
US-20110274648-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-11-10 — — US disclosed
WO-2011059887-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 — — WO disclosed
WO-2011059850-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 — — WO disclosed
EP-0918768-B1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C RES LAB (KR) 2002-01-09 — — EP disclosed
US-6201006-B1 ANTICOAGULANTS C & C RESEARCH LABORATORIES (KR) 2001-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP HSD17B10 4251/4885CHRM2 3142/4885CHRM1 3007/4885
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 PF4, F12, F2 HSD17B10 1989/4885CHRM2 1605/4885CHRM1 1357/4885
US-20250059171-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ACE, EIF2AK2 HSD17B10 1647/4885CHRM2 4883/4885CHRM1 4868/4885
US-20110274648-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS HSD17B10 1305/4885CHRM2 4697/4885CHRM1 4713/4885
US-20130115193-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS HSD17B10 1305/4885CHRM2 4697/4885CHRM1 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.